Pacific Biosciences of California (PACB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual meeting scheduled for June 3, 2026, with virtual attendance available for shareholders.
Shareholders are encouraged to review proxy materials and vote by June 2, 2026.
Voting matters and shareholder proposals
Election of six directors: William Ericson, Chris Gibson, Ph.D., Christian O. Henry, John F. Mulligan, Ph.D., Kathy Ordoñez, and Christopher M. Smith.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve compensation of named executive officers.
Approval of amendment to the 2020 Equity Incentive Plan.
Proxies may vote on other business arising at the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals.
Latest events from Pacific Biosciences of California
- Proxy covers director elections, auditor ratification, compensation, and equity plan amendment.PACB
Proxy filing23 Apr 2026 - Record consumables growth, margin gains, and $48M asset sale set up for up to 12% growth in 2026.PACB
Q4 202513 Apr 2026 - SPARQ-Nx chemistry and global clinical expansion set the stage for accelerated growth in 2026.PACB
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Clinical expansion, innovation, and margin gains drive growth amid global market shifts.PACB
TD Cowen 45th Annual Healthcare Conference3 Feb 2026 - All proposals passed, with leadership addressing share price declines and affirming strategic focus.PACB
AGM 20243 Feb 2026 - Q2 revenue fell on weak instrument sales, but consumables rose 24% and cost controls took effect.PACB
Q2 20242 Feb 2026 - Gross margin gains, R&D progress, and strong sales funnel signal a positive outlook.PACB
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Callisto automation delivers high-quality libraries with less labor, cost, and greater scalability.PACB
Status Update19 Jan 2026 - Q3 revenue rose sequentially as new products and debt restructuring set up future growth.PACB
Q3 202415 Jan 2026